Roche cuts muscle-sparing obesity drug after mid-stage disappointment
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
Roche
Biopharmaceutical company - Diagnostics
Company Info
Recent News
Roche culls myostatin candidate from obesity pipeline
Roche has abandoned the development of one of its obesity candidates, emugrobart, and returned rights to originator Chugai Pharma.
Roche's Gazyva secures FDA nod in 2nd autoimmune indication
Roche's Gazyva secures FDA nod in 2nd autoimmune indication
Roche kidney drug's Phase 3 win sets up path to accelerated approval
Roche moves closer to entering an increasingly crowded kidney disease market where Novartis, Calliditas, Travere, Otsuka and Vera already have approved drugs.
Roche eyes label expansion for Lunsumio after confirmatory lymphoma trial win
Roche eyes label expansion for Lunsumio after confirmatory lymphoma trial win
Roche turns to Dualitas to find new bispecific approaches for immunology
Roche turns to Dualitas to find new bispecific approaches for immunology
Roche sweeps neurology corporate reputation rankings once again
Roche sweeps neurology corporate reputation rankings once again
Roche taps Simcere for autoimmune trispecific for $1.53bn
Article from Pharmaphorum about Roche taps Simcere for autoimmune trispecific for $1.53bn.
Why Roche is 'really excited' about UCN2's obesity potential
Why Roche is 'really excited' about UCN2's obesity potential
Qiagen owes 10x, Roche $4.8 million for infringing patents, U.S. jury says
Qiagen owes 10x, Roche $4.8 million for infringing patents, U.S. jury says
Roche bets $1B+ on DualityBio's ADC tech to tackle payload resistance
Roche bets $1B+ on DualityBio's ADC tech to tackle payload resistance
Roche-Hanmi, Akeso, a congressman's concerns—Fierce Pharma Asia
Roche-Hanmi, Akeso, a congressman's concerns—Fierce Pharma Asia
Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA
Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA
Roche's Genentech strikes $2.3bn deal for Hanmi obesity drug HM17321
Roche's Genentech strikes $2.3bn deal for Hanmi obesity drug HM17321
Roche drops lupus TCE, retains autoimmune cell therapy interest
Roche drops its lupus T-cell engager program but retains broader autoimmune cell therapy ambitions following pipeline review.
Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add M&A
Roche CEO Schinecker says the company's late-stage pipeline is "so full" he's not feeling pressure to pursue major M&A.
Roche KRAS drug succeeds in head-to-head lung cancer study
Roche KRAS drug succeeds in head-to-head lung cancer study (reported by BioPharma Dive)
Roche orchestrates phase 3 lung cancer win over Amgen and BMS
Roche orchestrates phase 3 lung cancer win over Amgen and BMS — Fierce Biotech coverage of biopharma industry developments.
Roche tops cancer reputation rankings as AstraZeneca climbs back
Roche tops cancer reputation rankings as AstraZeneca climbs back. (Fierce Pharma.)
With New Phase 3 Data, Roche Claims an Edge Over Amgen and BMS Lung Cancer Drugs
With New Phase 3 Data, Roche Claims an Edge Over Amgen and BMS Lung Cancer Drugs — MedCity News coverage of biopharma industry developments.